The joint supplement market for dogs is worth hundreds of millions of pounds annually. It’s built on a combination of genuine veterinary concern about joint disease, a population of owners who understandably want to do everything possible for their dogs, and marketing that runs considerably ahead of the evidence.
I’ve been recommending and occasionally advising against joint supplements for the entirety of my career. My thinking has evolved considerably, and not in the direction of greater enthusiasm for most of the products out there.
Let me tell you what I actually think.
Why This Conversation Matters for Herding Breeds
Herding breeds are at elevated risk for joint disease. German Shepherds, with their high rates of hip dysplasia and their characteristic sloped rear conformation, develop arthritis earlier and more severely than many other breeds. Border Collies, Australian Shepherds, and other active working dogs place enormous repetitive demands on their joints across years of work. Elbow dysplasia, cruciate disease, and osteochondrosis are all disproportionately represented in working herding breed populations.
The commercial opportunity this creates is enormous. If your dog has compromised joints, you want to help. You’ll spend money to help. And supplement manufacturers know this.
That doesn’t mean all supplements are useless. Some have genuine evidence behind them. Others are largely expensive placebos. The challenge is telling them apart, which requires actually looking at the studies rather than reading the packaging.
Glucosamine and Chondroitin
These are the most widely used joint supplements in both human and veterinary medicine. The theory is sound: glucosamine is a building block for cartilage; chondroitin helps maintain cartilage structure and inhibit some of the enzymes that degrade it. Give them orally, the argument goes, and you support the joint’s structural integrity.
The reality is more complicated.
The evidence from human trials — which are better designed and more numerous than veterinary trials — is modest at best. The GAIT trial, the largest human study, found that glucosamine and chondroitin together had minimal effect compared to placebo in the overall population, with a possible effect in the subgroup with moderate-to-severe arthritis. Subsequent systematic reviews have been similarly lukewarm.
Veterinary evidence is even thinner. There are positive studies, but many are small, poorly controlled, or funded by supplement manufacturers, which introduces bias that makes interpretation difficult. Honest summary: glucosamine and chondroitin may have a modest beneficial effect in some dogs, they have a good safety profile, and they probably aren’t dramatic.
If you’re already using them and feel your dog is doing better, I won’t argue against continuing. Placebo effect on the owner-observer is real and may result in genuinely better care of a dog. And some dogs genuinely do respond.
What I will say: the quality and bioavailability of glucosamine products varies enormously. Veterinary formulations with documented bioavailability data are more reliable than products from the pet shop shelf, where what’s claimed on the label may not reflect what’s actually delivered at the joint level.
Omega-3 Fatty Acids: The One I Recommend With Conviction
Of all the joint supplements discussed in veterinary practice, omega-3 fatty acids from marine sources have the best evidence base. Not extraordinary evidence — nothing about supplements has extraordinary evidence — but the best we’ve got.
The mechanism is real. Omega-3 fatty acids, particularly EPA and DHA from fish oil, compete with arachidonic acid in the inflammatory cascade. The result is production of less inflammatory prostaglandins and leukotrienes. This isn’t a theoretical effect; it’s been measured in both in vitro and in vivo studies.
Clinically, several decent trials in dogs with osteoarthritis have found meaningful improvements in objective gait analysis, observer-assessed scores, and NSAID requirements in dogs receiving therapeutic doses of omega-3 fatty acids. The effects aren’t enormous, but they’re real.
For herding breeds with joint disease, I routinely recommend fish oil supplementation as part of the management plan. The dose matters — the anti-inflammatory effect requires proper therapeutic dosing, not the low doses in many commercial products. Discuss appropriate dosing with your vet based on your dog’s body weight.
A few practical considerations:
Source quality matters. Fish oil should be from wild-caught, tested sources. Rancidity is a problem with fish oil products — a rancid oil not only has reduced efficacy but may cause oxidative damage. Smell the capsules; they should not smell unpleasant.
Stability matters. Omega-3 fatty acids oxidise. Some products use antioxidant stabilisers to address this; keep them in cool, dark storage.
Don’t confuse plant-based omega-3 (ALA from flaxseed) with marine-based (EPA/DHA). Dogs convert ALA to EPA/DHA very inefficiently. The anti-inflammatory benefits require EPA and DHA directly. This is why fish oil and green-lipped mussel work where flaxseed doesn’t.
Green-Lipped Mussel
Green-lipped mussel (Perna canaliculus) is a New Zealand shellfish that contains omega-3 fatty acids, glycosaminoglycans, and a range of other compounds with proposed joint benefits. It’s been heavily marketed in veterinary circles, and some of the earlier enthusiasm has cooled as better studies have emerged.
The evidence, reviewed honestly: there are positive trials, but many are small and of moderate quality. The most recent systematic reviews suggest a possible modest benefit in canine osteoarthritis, particularly for pain and lameness outcomes.
My view is that green-lipped mussel products may be worth trying in dogs where omega-3 supplementation alone hasn’t achieved adequate management, particularly given that the combination of compounds may have additive effects. They have a good safety profile. Whether they’re worth the typically higher cost compared to straightforward fish oil supplementation is less clear.
Polysulphated Glycosaminoglycans: The Injectable Option
Pentosan polysulphate (Cartrophen) and similar injectable glycosaminoglycan preparations are in a different category from the oral supplements above. They’re prescription medicines, given by injection, and they have better evidence than most oral supplements.
The mechanism involves multiple pathways: stimulating synthesis of proteoglycans in cartilage, inhibiting destructive enzymes, reducing inflammation, and improving joint fluid quality. The clinical evidence for modest improvements in mobility and pain in canine osteoarthritis is reasonably consistent.
For dogs in the early to moderate stages of hip or elbow arthritis, a course of Cartrophen injections is something I discuss and often recommend. It’s not a dramatic intervention, but it’s one of the more evidence-supported pharmacological approaches we have outside NSAIDs. It can also be useful in dogs where NSAIDs aren’t well-tolerated.
Avocado and Soybean Unsaponifiables
This one sounds odd but has some veterinary evidence behind it. Extracts from avocado and soybean oils have been shown in several canine trials to have anti-inflammatory and chondroprotective effects. Products containing these extracts are available, mostly through veterinary channels.
The evidence is better than for glucosamine but the products are less widely used, possibly because they’re less commercially visible. Worth knowing about for dogs with established joint disease not achieving adequate control through other approaches.
What I Actually Tell My Clients
Here’s the practical framework I use when a herding breed comes in with joint disease:
Priority one: Weight management. No supplement makes up for excess weight loading a compromised joint. If the dog isn’t lean, the conversation starts there. I’ve written about why weight management matters so much for herding breeds with joint problems — it’s worth revisiting if you haven’t already.
Priority two: Exercise management — appropriate, regular, low-impact. Joint cartilage needs movement; the goal is the right kind of movement, not restriction.
Priority three: Fish oil at therapeutic dose. Start this immediately and run it as a background supplement indefinitely. The evidence supports it better than anything else in this category.
Priority four: Pain management with your vet. If the dog needs NSAIDs, use them consistently with appropriate monitoring. Don’t substitute supplements for adequate pain control.
Priority five: Consider Cartrophen injections for dogs with established arthritis who haven’t had them.
Optional additions: Glucosamine/chondroitin if the owner wants to add them — modest potential benefit, low risk. Green-lipped mussel if looking for additional options.
What I’d skip: The majority of “joint health” products with complex ingredient lists and impressive marketing but no real evidence. The shelf of a pet shop is not a substitute for veterinary advice.
The Connection to Long-Term Mobility
Managing joint health in herding breeds isn’t just about comfort in middle age. It’s about the trajectory across a decade or more of life. The dog that goes into its senior years with well-managed joints, lean body condition, and appropriate pain control is going to have a dramatically different quality of life from the dog that limps in at eight years old having received no preventive management.
Everything I’ve discussed here feeds into the broader picture of senior herding breed health — the arthritis, the muscle wasting, the reduced mobility that define the senior dog experience. Joint supplement decisions made at five or six years old are investments in the senior dog you’ll be managing at ten or twelve.
Make those investments based on evidence rather than marketing. It costs less and works better.